Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) has announced the presentation of preclinical data for OTO-825, a gene therapy for congenital hearing loss, at the American Society of Gene & Cell Therapy (ASGCT) Meeting from May 16-19 in Washington, DC. Dr. Phillip Uribe will present findings on May 19 at 11:15 a.m. ET, focusing on OTO-825's development for GJB2 deficiency. Otonomy specializes in innovative therapeutics for neurotology, particularly aimed at addressing hearing loss and tinnitus through advanced drug delivery technology.

Positive

• Presentation of promising preclinical data for OTO-825 at a prominent conference.
• Focused on significant medical needs in congenital hearing loss, expanding Otonomy's product pipeline.

Negative

• None.

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming American Society of Gene & Cell Therapy (ASGCT) Meeting being held May 16-19 in Washington, DC.

Dr. Phillip Uribe from Otonomy will be making a podium presentation entitled “Preclinical Development of an AAV-based Gene Therapy (OTO-825) for Congenital Hearing Loss Due to GJB2 Deficiency” beginning at 11:15 a.m. ET on May 19. This presentation is included in the “Breakthroughs in Neuromuscular and Hearing Disorders” session of the ASGCT meeting.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Lauren Benton
Senior Account Executive
212.899.9731
lbenton@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

What is the significance of Otonomy's presentation at the ASGCT Meeting?

Otonomy is presenting preclinical data for OTO-825, focusing on gene therapy for congenital hearing loss, which could advance treatment options.

When is the presentation for OTO-825 scheduled?

The presentation is scheduled for May 19 at 11:15 a.m. ET.

What is OTO-825 designed to treat?

OTO-825 is designed to treat congenital hearing loss due to GJB2 deficiency.

What type of therapy is OTO-825?

OTO-825 is an AAV-based gene therapy.

Where can I find more information about Otonomy?

More information can be found on Otonomy's website at www.otonomy.com.